Evidence map›Paper›PMID 41683683›Full record

ArticleInternational journal of molecular sciences2026

Immune and Endothelial-Related Extracellular Vesicles Are Associated with Corticosteroid Response and Mortality in Alcohol-Associated Hepatitis.

Albert Guinart-Cuadra, Anna Brujats, Justyna Szafranska, Rubén Guerrero, Fernándo Dinamarca, Elisabet Cantó, Maria Poca, Eva Román, Elisabet Sánchez-Ardid, Javier Fajardo and 14 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Albert Guinart-CuadraGroup of Inflammatory Diseases, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0000-0003-0233-5595
Anna BrujatsCentre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-3317-0295
Justyna SzafranskaDepartment of Pathology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Rubén GuerreroDepartment of Interventional Radiology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Fernándo DinamarcaDepartment of Psychiatry, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain.
Elisabet CantóGroup of Inflammatory Diseases, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0000-0002-1782-1855
Maria PocaCentre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-0235-1395
Eva RománCentre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-9084-8555
Elisabet Sánchez-ArdidCentre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Javier FajardoGastroenterology and Hepatology Department, Hospital de la Santa Creu i Sant Pau, Department of Medicine, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain.
Montserrat CampsGastroenterology and Hepatology Department, Hospital de la Santa Creu i Sant Pau, Department of Medicine, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain.
Maria MuletGroup of Inflammatory Diseases, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0000-0003-3639-3291
German SorianoCentre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-9267-6811
Àngels EscorsellGastroenterology and Hepatology Department, Hospital de la Santa Creu i Sant Pau, Department of Medicine, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain.ORCID 0000-0001-5083-8467
Juan M Falcon-PerezCentre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-3133-0670
Esperanza GonzalezExosomes Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Elaxalde Derio, Bizkaia, Spain.ORCID 0000-0002-3831-4596
Andreu Ferrero-GregoriGastroenterology and Hepatology Department, Hospital de la Santa Creu i Sant Pau, Department of Medicine, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain.ORCID 0000-0001-6492-2416
Cristina GelyGastroenterology and Hepatology Department, Hospital de la Santa Creu i Sant Pau, Department of Medicine, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain.
Jorge VillalbaDepartment of Interventional Radiology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Ramón BatallerLiver Unit, Department of Digestive and Metabolic Diseases, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Josepmaria ArgemiCentre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Rubén Osuna-GómezGroup of Inflammatory Diseases, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0000-0003-2875-4405
Silvia VidalGroup of Inflammatory Diseases, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0000-0002-3909-6682
Edilmar Alvarado-TapiasGroup of Inflammatory Diseases, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.ORCID 0000-0003-2036-6133

Funding

Instituto de Salud Carlos III PI21/01995
6 · The paper itself

Abstract

Alcohol-associated hepatitis (AH) is the most severe clinical manifestation of alcohol-associated liver disease. Corticosteroids are the only disease-specific therapy shown to improve short-term survival. Currently, no non-invasive markers are available to predict patient response to corticosteroids or long-term survival in AH. This study investigates whether surface antigens on plasma extracellular vesicles (EVs), key mediators of intercellular communication, can reflect the underlying immune dysregulation in AH and serve as prognostic markers. Patients with AH were prospectively enrolled between 2020 and 2024. Blood samples were collected before corticosteroid initiation during the first 24 h of hospitalization. EVs were characterized using nanoparticle tracking analysis, cryo-electron microscopy, and flow cytometry. Interleukin-6 (IL-6), soluble (s)CD62p, Circulating Vascular Cell Adhesion Molecule-1 (sVCAM), tumor necrosis factor receptor superfamily member 1 (TNRFS1a), and Intercellular Adhesion Molecule 1 (ICAM-1) were quantified by ELISA. Key outcome variables included response to corticosteroids and mortality. A total of 46 patients with AH and 28 healthy donors (HD) were included. EV concentration was significantly higher in AH patients than in HD (9.3 × 10

Indexed as

Adrenal Cortex HormonesExtracellular VesiclesHepatitis, AlcoholicAdultBiomarkersFemaleHumansInterleukin-6MaleMiddle AgedPrognosisAdrenal Cortex HormonesBiomarkersInterleukin-6alcohol-associated hepatitiscorticosteroid responseextracellular vesicles

Identifiers

PMID41683683
PMCPMC12897947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.